Request an Appointment
Current Patients

The Specialty Care Gap: Why Finding the Right Treatment Is So Hard

By Cody Gustaveson, PhD — President and Clinical Director, Clinic Ovis

Most people who walk into a mental health clinic in the United States are not seen by a specialist. They are seen by whoever has an opening. For many conditions that works fine. For others, it means years of treatment that was never designed for the problem they actually have.

Clinic Ovis started with two conditions, obsessive-compulsive disorder and insomnia, because they are the clearest examples of this gap: both are common, both have a first-line treatment with decades of evidence, and both are routinely treated with something else. But the gap is bigger than either diagnosis, and closing it is the point of this practice. This post lays out the problem with the numbers behind it.

OCD: a common disorder, rarely treated correctly

OCD affects about 2.3% of American adults over their lifetime and 1.2% in any given year.1 Half of those with active OCD are seriously impaired, losing an average of 46 days a year to the disorder.2 It usually begins in adolescence.2

It is also one of the most treatable conditions in psychiatry, if the right treatment is used. Exposure and response prevention (ERP), a specific form of cognitive-behavioral therapy, produced response in 86% of patients who completed it in the landmark U.S. trial, compared with 48% on medication and 10% on placebo.3 A 2021 meta-analysis of 36 randomized trials confirmed large effects.4

And yet:

  • Adults in the Brown Longitudinal OCD Study first received treatment more than 17 years after their symptoms began.5 A 2025 analysis of records from more than ten million U.S. patients still found an average of 7 years from symptoms to diagnosis.6
  • In vignette studies, 39% of psychologists and 51% of primary care physicians failed to recognize textbook OCD; presentations involving taboo intrusive thoughts were missed 70% to 85% of the time.7,8
  • Only about 20% of adults with past-year OCD receive treatment specifically for OCD.2 Among U.S. psychiatrists’ OCD patients, just 7.5% received CBT.9 In the 2025 records analysis, 2% of diagnosed patients had received ERP and more than 70% were never referred for it.6
  • Surveys of practicing U.S. therapists find exposure techniques used in roughly a third of eligible cases or fewer, even among clinicians who describe their work as CBT.10,11

Longer delays are not just painful; they predict weaker response once treatment finally starts.12

Insomnia: a first-line treatment almost nobody is offered

Insomnia is even more common. About 10% of U.S. adults meet criteria for chronic insomnia disorder.13 Since 2016 the American College of Physicians has recommended cognitive-behavioral therapy for insomnia (CBT-I) as the initial treatment for every adult patient, ahead of medication, and the American Academy of Sleep Medicine issued the same strong recommendation in 2021.14,15 Across 87 randomized trials, CBT-I produces large, durable improvements without the side effects or dependence that come with sedatives.16

What patients actually receive is medication. In the most recent CDC data, 8.4% of American adults take a sleep medication every day or most days.17 When physicians at two U.S. academic medical centers were surveyed, they saw an average of 15 insomnia patients a month and referred fewer than two of them for CBT-I; only 9% believed CBT-I alone was the most effective treatment.18 The reason is not hard to find. A national census identified just 659 behavioral sleep medicine providers in the entire United States, concentrated in a dozen states, with 105 of the country’s 167 largest cities having none at all.19 Untreated insomnia, meanwhile, costs U.S. employers an estimated $63 billion a year in lost productivity.20

The pattern generalizes

Replace “OCD” or “insomnia” with PTSD, panic disorder, health anxiety, or a child who needs a proper psychological evaluation, and the shape of the problem is the same. Each has a first-line, well-studied treatment. Each is routinely delivered instead as generic supportive therapy, because that is what the available clinician is trained to do. The patient improves a little, or not at all, concludes that therapy does not work for them, and stops looking.

The workforce numbers explain why. About 137 million Americans, 40% of the population, live in a federally designated mental health professional shortage area, including 11.5 million Californians.21 San Diego County alone was estimated in 2022 to be short roughly 8,000 behavioral health workers.22 When the general workforce is that thin, sub-specialty expertise is thinner still, and it concentrates in academic medical centers and boutique private practices rather than in the community clinics most people can actually reach.

The second wall: cost

For the patient who does locate a specialist, the next barrier is financial. Only 55% of U.S. psychiatrists accept private insurance, compared with 89% of physicians in other specialties, and the gap is wider for Medicaid.23 At least a third of therapists in private practice take no insurance at all.6 Specialty self-pay rates commonly run $250 to $350 per session, so a standard course of 12 to 20 sessions costs several thousand dollars out of pocket; intensive and residential programs run to hundreds or thousands of dollars per day.24 When people with OCD are asked why they did not get evidence-based care, cost and lack of insurance sit alongside shame near the top of the list.25

The result is a two-tier system. Specialized care exists, but it is largely reserved for people who can travel to it and pay cash for it. Everyone else gets what the local clinic offers.

Raising the standard for the local clinic

That is the problem Clinic Ovis is built around. The goal is not to be another boutique practice, but to show that a community clinic, the kind a patient finds through their insurance directory or a referral from their family doctor, can deliver specialty-level care at the standard the research supports.

That means a few concrete commitments. Clinicians are trained in the specific evidence-based protocols for the conditions we treat, and we deliver them as they were studied rather than in diluted form. We use psychological testing when the diagnostic picture is unclear, because the right treatment starts with the right name. And we are in-network with Aetna, Anthem Blue Cross, Medicare, TriWest (TRICARE), and UnitedHealthcare/Optum, with a Good Faith Estimate up front for anyone paying out of pocket, because the evidence is unambiguous that cost is what keeps people out.

We began with OCD and insomnia because the gap there is widest and easiest to measure. The aim is the same across everything we do: the person who walks in should get the treatment that works, on the first try, without needing to be wealthy or lucky to find it.

If you have been in treatment that never quite addressed the problem, or you are a provider with a patient who needs specialty care, request an appointment or make a referral.

References

  1. National Institute of Mental Health. Obsessive-Compulsive Disorder (OCD) Statistics. https://www.nimh.nih.gov/health/statistics/obsessive-compulsive-disorder-ocd
  2. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry. 2010;15(1):53–63.
  3. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 2005;162(1):151–161.
  4. Reid JE, Laws KR, Drummond L, et al. Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials. Comprehensive Psychiatry. 2021;106:152223.
  5. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. Journal of Clinical Psychiatry. 2006;67(5):703–711.
  6. International OCD Foundation. America’s OCD Care Crisis. December 2025. https://iocdf.org/wp-content/uploads/2025/12/Full-Report-Americas-OCD-Care-Crisis-12-9-2025.pdf
  7. Glazier K, Calixte RM, Rothschild R, Pinto A. High rates of OCD symptom misidentification by mental health professionals. Annals of Clinical Psychiatry. 2013;25(3):201–209.
  8. Glazier K, Swing M, McGinn LK. Half of obsessive-compulsive disorder cases misdiagnosed: vignette-based survey of primary care physicians. Journal of Clinical Psychiatry. 2015;76(6):e761–e767.
  9. Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by U.S. psychiatrists. Journal of Clinical Psychiatry. 2006;67(6):946–951.
  10. Hipol LJ, Deacon BJ. Dissemination of evidence-based practices for anxiety disorders in Wyoming: a survey of practicing psychotherapists. Behavior Modification. 2013;37(2):170–188.
  11. Reid AM, Guzick AG, Fernandez AG, et al. Exposure therapy for youth with anxiety: utilization rates and predictors of implementation in a sample of practicing clinicians from across the United States. Journal of Anxiety Disorders. 2018;58:8–17.
  12. Albert U, Barbaro F, Bramante S, et al. Duration of untreated illness and response to SRI treatment in obsessive-compulsive disorder. European Psychiatry. 2019;58:19–26.
  13. American Academy of Sleep Medicine. New guideline supports behavioral, psychological treatments for insomnia. December 2020. https://aasm.org/new-guideline-supports-behavioral-psychological-treatments-for-insomnia/
  14. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125–133.
  15. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2021;17(2):255–262.
  16. van Straten A, van der Zweerde T, Kleiboer A, Cuijpers P, Morin CM, Lancee J. Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis. Sleep Medicine Reviews. 2018;38:3–16.
  17. Reuben C, Elgaddal N, Black LI. Sleep medication use in adults aged 18 and over: United States, 2020. NCHS Data Brief No. 462. January 2023. https://www.cdc.gov/nchs/data/databriefs/db462.pdf
  18. Conroy DA, Ebben MR. Referral practices for cognitive behavioral therapy for insomnia: a survey study. Behavioural Neurology. 2015;2015:819402.
  19. Thomas A, Grandner M, Nowakowski S, Nesom G, Corbitt C, Perlis ML. Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment. Behavioral Sleep Medicine. 2016;14(6):687–698.
  20. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America Insomnia Survey. Sleep. 2011;34(9):1161–1171.
  21. Kaiser Family Foundation. Mental Health Care Health Professional Shortage Areas (HPSAs). Data as of December 31, 2025. https://www.kff.org/other-health/state-indicator/mental-health-care-health-professional-shortage-areas-hpsas/
  22. San Diego Workforce Partnership. Addressing San Diego’s Behavioral Health Worker Shortage. August 2022. https://workforce.org/wp-content/uploads/2022/08/San-Diego-Behavioral-Health-Workforce-Report-.pdf
  23. Bishop TF, Press MJ, Keyhani S, Pincus HA. Acceptance of insurance by psychiatrists and the implications for access to mental health care. JAMA Psychiatry. 2014;71(2):176–181.
  24. Session and program fees reflect publicly posted rates from U.S. specialty practices and treatment programs as of 2026; actual costs vary by provider and region.
  25. Marques L, LeBlanc NJ, Weingarden HM, Timpano KR, Jenike M, Wilhelm S. Barriers to treatment and service utilization in an internet sample of individuals with obsessive-compulsive symptoms. Depression and Anxiety. 2010;27(5):470–475.